| Literature DB >> 27871245 |
Setegn Eshetie1, Fentahun Tarekegn2, Feleke Moges3, Anteneh Amsalu3, Wubet Birhan3, Kahsay Huruy3.
Abstract
BACKGROUND: The burden of methicillin resistant Staphylococcus aureus is a major public health concern worldwide; however the overall epidemiology of multidrug resistant strains is neither coordinated nor harmonized, particularly in developing countries including Ethiopia. Therefore, the aim of this meta-analysis was to assess the burden of methicillin resistant Staphylococcos aureus and its antibiotic resistance pattern in Ethiopia at large.Entities:
Keywords: Ethiopia; Meta-analysis; Methicillin resistant Staphylococcus aureus; Systematic review
Mesh:
Substances:
Year: 2016 PMID: 27871245 PMCID: PMC5117566 DOI: 10.1186/s12879-016-2014-0
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Flow chart shows selected articles for meta-analysis
Fig. 2Forest plot of the pooled prevalence of MRSA in 20 studies, Ethiopia, 2004–2015
Summary of 20 studies reporting the prevalence of MRSA in different parts of Ethiopia, 2004-2015
| Region | Study area | Study period | Study design | Study population | Culture specimens | No of S. aureus isolates | Percentage of MRSA, N (%) | References |
|---|---|---|---|---|---|---|---|---|
| Amhara | Bahirdar, Dessie and Debre Tabor | December 2013 to April 2014 | Cross-sectional study | HIV infected pediatric patients | Skin swab, nasal swab, and perineum swab | 281 | 73 (26) | Lemma et al. 2015 [ |
| Gondar | February to May 2012 | Cross-sectional study | VL patients | Blood | 11 | 2 (18.2) | Endris et al. 2014 [ | |
| Gondar | July 2011 to June 2012 | Cross-sectional study | Neonates | Blood | 17 | 7 (41.2) | Gebrehiwot et al. 2012 [ | |
| Gondar | January to June 2011 | Cross-sectional study | Food handlers | Nasal swab | 41 | 4 (9.8) | Dagnew et al. 2012 [ | |
| Gondar | September 2009 to June 2010 | Cross-sectional study | In and out patient | Urine, eye discharge, genital swab, body fluid, pus, wound swab and discharge | 279 | 49 (17.6) | Anagaw et al. 2013 [ | |
| Gondar | January to June 2010 | Cross-sectional study | Patients with post-operative surgical site Infections | Pus swab | 26 | 9 (34.6) | Amare et al. 2012 [ | |
| Bahirdar | April to June 2006 | Cross-sectional study | In and out patient | surgical wound, ear discharges, eye discharges and throat swabs | 162 | 89 (54.9) | Abera et al. 2008 [ | |
| Debre Markos | March to June 2013 | Cross-sectional study | School children | Nasal swab | 123 | 17 (13.8) | Reta et al. 2015 [ | |
| Debre Markos | December 2011 to March 2012 | Cross-sectional study | Patients with surgical site infection | Wound swab | 73 | 36 (49.7) | Kahsay et al. 2014 [ | |
| Dessie | November 2010 to March 2011 | Cross-sectional study | Healthcare workers | Nasal swab | 34 | 15 (44.1) | Shibabaw et al. 2013 [ | |
| Oromia | Jimma | June to December 2011 | Cross-sectional study | In and out patient | Wound swab | 73 | 56 (76.7) | Godebo et al. 2013 [ |
| Jimma | December 2010 to June, 2011 | Cross-sectional study | Primary school children and prisoners | Nasal swab | 169 | 39 (23.1) | Kejela and Bacha, 2013 [ | |
| Jimma | January 2003 to July 2004 | Cross-sectional study | Out patients | Ear discharges, throat and wound swabs | 72 | 6 (8.3) | Gebre-Sealsssie, 2007 [ | |
| Harar and Jimma | - | Cross-sectional study | --- | Blood, CSF, pus, sputum and urine | 210 | 103 (49) | Rasheed and Ahmed, 2010 [ | |
| Central Ethiopia | Addis Ababa | March to August 2015 | Cross-sectional study | Post operative patients | Wound swab | 56 | 6 (10.7) | Getachew et al. 2015 [ |
| Addis Ababa | September 2013 to April 2014 | Cross-sectional study | In and out patient | Nasal swab, wound swab, ear discharge, blood, throat swab, eye swab, vaginal discharge, urethral discharge, urine, stool, sputum, CSF and body fluids | 194 | 34/(17.5) | Tebelay et al. 2014 [ | |
| Addis Ababa | March to May 2011 | Cross-sectional study | In and out patient (burn patients) | Wound swab | 66 | 51 (77.3) | Alebachew et al. 2012 [ | |
| Addis Ababa | April to July 2010 | Cross-sectional study | In and out patient (burn patients) | Blood and wound swabs | 24 | 5 (20.8) | Sewunet et al. 2013 [ | |
| Tigray | Mekelle | November 2010 to January 2011 | Cross-sectional study | Health care workers | Nasal swab and material from hand | 177 | 36 (20.3) | Gebreyesus et al. 2013 [ |
| Southern Ethiopia | Hawassa | August 2013 to December 2014 | Cross-sectional study | Health care workers | Sample from hand and mobile phones | 166 | 67 (40.2) | Daka, 2014 [ |
Keys: CSF Cerebro-spinal fluid, HIV Human immuno-deficiency virus, VL Visceral leshimaniasis
Fig. 3Proportion of MRSA in different regions of Ethiopia, 2004–2015
Pooled antibiotic resistance rates of MRSA strains; Ethiopia, 2006-2014
| Antibiotics | Antibiotic resistance rate reported by 7 studies | Pooled resistance rate, % (95 % CI) | ||||||
|---|---|---|---|---|---|---|---|---|
| Lemma et al. 2015 [ | Anagaw et al. 2013 [ | Abera et al. 2008 [ | Kahsay et al. 2014 [ | Reta et al. 2015 [ | Kejela & Bacha, 2013 [ | Tebelay et al. 2014 [ | ||
| Chloramphinicol | 4 (5.5) | 22 (44.9) | - | - | 0 | 23 (59) | 16 (47.1) | 30.8 (30.3–63.8) |
| Ceftriaxone | 15 (20.5) | 2 (4.1) | 85 (95.5) | - | 0 | - | 30.8 (0–84.1) | |
| Ciprofloxacin | 17 (23.3) | 2 (4.1) | 67 (75.3) | - | 0 | - | 28 (82.4) | 37.3 (5.9–68.7) |
| Clindamycin | 6 (8.2) | 1 (2) | - | 22 (61.1) | 0 | - | 18 (52.9) | 23.1 (7.5–38.8) |
| Cotrimoxazole | 4 (5.5) | 22 (44.9) | - | 36 (100) | 2 (11.8) | 7 (17.9) | 34 (100) | 46.4 (8.4–84.5) |
| Erythromycin | 17 (23.3) | 9 (18.4) | 69 (77.5) | 35 (97.2) | 0 | 24 (61.5) | 34 (100) | 97.2 (23.2–100) |
| Tetracycline | 53 (72.6) | 10 (20.4) | 80 (89.9) | 15 (41.7) | - | 13 (33.3) | - | 51.9 (22.8–81) |
| Pencillin G | - | 49 (100) | 89 (100) | 36 (100) | 17 (100) | 39 (100) | 34 (100) | 99.1 (98–100) |
| Ampicillin | - | 46 (93.9) | - | 36 (100) | - | 39 (100) | - | 98.1 (95.7–100) |
| Amoxacillin | - | 46 (93.9) | - | 36 (100) | - | - | 97.1 (92.7–100) | |
| Vancomycin | - | 0 | 0 | - | - | 5 (12.8) | 10 (29.4) | 5.3 (0–10.6) |
| Gentamycin | - | - | 63 (70.8) | 34 (94.4) | 0 | 6 (15.4) | 13 (38.2) | 44.4 (4.9–83.9) |